[go: up one dir, main page]

WO1993025698A9 - Particules vecteurs resistantes a l'inactivation par le serum humain - Google Patents

Particules vecteurs resistantes a l'inactivation par le serum humain

Info

Publication number
WO1993025698A9
WO1993025698A9 PCT/US1993/004706 US9304706W WO9325698A9 WO 1993025698 A9 WO1993025698 A9 WO 1993025698A9 US 9304706 W US9304706 W US 9304706W WO 9325698 A9 WO9325698 A9 WO 9325698A9
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
protein
changed
vector particle
mutated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1993/004706
Other languages
English (en)
Other versions
WO1993025698A1 (fr
Filing date
Publication date
Application filed filed Critical
Priority to JP6501479A priority Critical patent/JPH09507741A/ja
Priority to EP93913964A priority patent/EP0644946A4/fr
Publication of WO1993025698A1 publication Critical patent/WO1993025698A1/fr
Publication of WO1993025698A9 publication Critical patent/WO1993025698A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Definitions

  • This invention relates to "injectable" vector particles. More particularly, this invention relates to vector particles, such as retroviral vector particles, wherein such vector particles are resistant to inactivation by human serum.
  • Vector particles are useful agents for introducing gene(s) or DNA (RNA) into a cell, such as a eukaryotic cell.
  • the gene(s) is controlled by an appropriate promoter.
  • vectors which may be employed to generate vector particles include prokaryotic vectors, such as bacterial vectors; eukaryotic vectors,' including fungal vectors such as yeast vectors; and viral vectors such as DNA virus vectors, RNA virus vectors, and retroviral vectors.
  • Retroviruses which have been employed for generating vector particles for introducing genes or DNA (RNA) into a cell include Moloney Murine Leukemia Virus, Spleen Necrosis Virus, Rous Sarcoma Virus and Harvey Sarcoma Virus.
  • the term "introducing” as used herein encompasses a variety of methods of transfering genes or DNA (RNA) into a cell. Such methods include transformation, transduction, transfection, and infection.
  • Vector particles have been used for introducing DNA (RNA) into cells for gene therapy purposes.
  • RNA DNA
  • such a procedure involves obtaining cells from a patient and using a vector particle to introduce desired DNA (RNA) into the cells and then providing the patient with the engineered cells for a therapeutic purpose.
  • RNA desired DNA
  • Such an alternative procedure would involve genetically engineering cells in vivo.
  • a vector particle which includes the desired DNA (RNA) would be administered to a patient for in vivo delivery to the cells of a patient.
  • a vector particle such as, for example, a retroviral vector particle
  • a vector particle which is resistant to inactivation by human serum.
  • the vector particle is a viral vector particle, and more preferably the viral vector particle is a retroviral vector particle.
  • retroviruses include a protein known as p15E, and Applicants have found that retroviruses are susceptible to inactivation by human serum as a result of the action of complement protein(s) present in serum on the p15E protein portion of the retrovirus. Applicants have further found that such retroviruses can be made resistant to inactivation by human serum by mutating such p15E protein.
  • a retroviral vector wherein a portion of the DNA encoding p15E protein (shown in the accompanying sequence listing), has been mutated to render the vector particle resistant to inactivation by human serum.
  • mutated and mutation as used herein mean that the DNA encoding p15E protein has been changed such that at least one but not all of the amino acids of p15E protein have been changed (such changes can include point mutations, deletions, and/or insertions).
  • p15E protein is a viral protein having 196 amino acid residues. In viruses, sometimes all 196 amino acid residues are present, and other times, amino acid residues 181 to 196 (known as the "r" peptide), are not present, and the resulting protein is the "mature" form of p15E known as p12E. Thus, viruses can contain both the p15E and p12E proteins.
  • p15E protein is anchored in the viral membrane such that amino acid residues 1 to 134 are present on the outside of the virus.
  • the p15E protein includes two regions, amino acid residues 39 to 61 (sometimes hereinafter referred to as region 1), and amino acid residues 101 to 123 (sometimes hereinafter referred to as region 2), which Applicants believe have an external location in the three-dimensional structure of the p15E protein; i.e., such regions are directly exposed to human serum.
  • Region 2 is a highly conserved region in many retroviruses, even though the amino acid sequences of this region are not identical in all retroviruses.
  • Such regions are complement binding regions. Examples of complement proteins which may bind to the complement binding regions are CIS and ClQ, which bind to regions 1 and 2.
  • complement proteins bind to both region 1 and region 2.
  • at least one portion of DNA encoding a complement binding region of p15E protein has been mutated.
  • Such a mutation results in a change of at least one amino acid residue of a complement binding region of p15E protein.
  • the change in at least one amino acid residue of a complement binding region of p15E protein prevents binding of a complement protein to the complement binding region, thereby preventing complement inactivation of the retrovirus.
  • at least one amino acid residue in both complement binding regions of p15E protein is changed, whereas in another embodiment, at least one amino acid residue in one of the complement binding regions is changed.
  • the at least one portion of DNA encoding p15E protein is mutated such that at least one positively charged amino acid residue or negatively charged amino acid residue is changed to an amino acid residue having the opposite charge.
  • the positively charged' amino acids are His, Lys, and Arg.
  • the negatively charged amino acids are Asp and Glu.
  • the at least one portion of DNA encoding p15E protein is mutated such that at least one positively charged amino acid or negatively charged amino acid is changed to a noncharged amino acid.
  • the at least one portion of DNA encoding a complement binding region of p15E protein which is mutated, encodes one or more of amino acid residues 101 to 123 of p15E protein. In one embodiment, the at least one portion of DNA encoding p15E protein is mutated such that amino acid residue 122 is changed.
  • the at least one portion of DNA encoding p15E protein is mutated such that at least one of amino acid residues 117 and 122 are changed.
  • amino acid residue 117 is changed from Arg to Glu
  • amino acid residue 122 is changed from Glu to Gln.
  • the at least one portion of DNA encoding p15E protein is mutated such that amino acid residues 104, 105, 109, and 111 are changed.
  • amino acid residue 104 is changed from Arg to His
  • amino acid residue 105 is changed from Asp to Asn
  • amino acid residue 109 is changed from Lys to Gln
  • amino acid residue 111 is changed from Arg to Gln.
  • the at least one portion of DNA encoding p15E protein is mutated such that amino acid residues 104, 105, 109, 111, 117, and 122 are changed.
  • the at least one portion of DNA is mutated such that amino acid residue 104 is changed from Arg to His, amino acid residue 105 is changed from Asp to Asn, amino acid residue 109 is changed from Lys to Gln, amino acid residue 111 is changed from' Arg to Gln, amino acid residue 117 is changed from Arg to Glu, and amino acid residue 122 is changed from Glu to Gln.
  • the mutation of DNA encoding p15E protein may be effected by deleting a portion of the p15E gene, and replacing the deleted portion of the p15E gene, with fragment(s) or portion(s) of a gene encoding another viral protein.
  • one portion of DNA encoding the p15E protein is replaced with a fragment of the gene encoding the p21 protein, which is an HTLV-I transmembrane protein.
  • HTLV-I virus has been found to be resistant to binding by complement proteins and thus HTLV-I is resistant to inactivation by human serum (Hoshino, et al., Nature, Vol. 310, pgs. 324-325 (1984)).
  • p15E protein is a protein having 176 amino acid residues, and which, in relation to p15E, has significant amino acid sequence homology.
  • at least amino acid residues 39 to 61, and 101 to 123 are deleted from p15E protein, and replaced with amino acid residues 34 to 56 and 96 to 118 of p21 protein.
  • at least amino acid residues 39 to 123 of p15E protein are deleted and replaced with amino acid residues 34 to 118 of p21 protein.
  • amino acid residues 39 to 69 of p15E protein are deleted and replaced with amino acid residues 34 to 64 of p21 protein, and amino acid residues 96 to 123 of p15E protein are deleted and replaced with amino acid residues 91 to 118 of p21 protein.
  • Vector particles thus generated, and which are resistant to inactivation by human serum may be engineered such that the vector particles may, when introduced into a patient, travel directly to a target cell or tissue.
  • the vector particle further includes a protein which contains a receptor binding region that binds to a receptor of a human target cell, such as, for example, but not limited to, the amphotropic cell receptor.
  • retroviral vectors hereinabove described may be constructed by genetic engineering techniques known to those skilled in the art.
  • the retroviral vector may be of the LN series of vectors, as described in Bender, et al., J.Virol., Vol. 61, pgs. 1639-1649 (1987) and Miller, et al., Biotechniques, Vol. 7, pgs. 980-990 (1989).
  • the retroviral vector includes a multiple restriction enzyme site, or multiple cloning site.
  • the multiple cloning site includes at least four cloning, or restriction enzyme sites, wherein at least two of the sites have an average frequency of appearance in eukaryotic genes of less than once in 10,000 base pairs; i.e., the restriction product has an average size of at least 10,000 base pairs.
  • restriction sites also sometimes hereinafter referred to as "rare" sites, which have an average frequency of appearance in eukaryotic genes of less than once in 10,000 base pairs, contain a CG doublet within their recognition sequence, such doublet appearing particularly infrequently in the mammalian genome.
  • Another measure of rarity or scarcity of a restriction enzyme site in mammals is its representation in mammalian viruses, such as SV40.
  • an enzyme whose recognition sequence is absent in SV40 may be a candidate for being a "rare" mammalian cutter.
  • restriction enzyme sites having an average frequency of appearance in eukaryotic genes of less than once in 10,000 base pairs include, but are not limited to the NotI, SnaBI, Sall, Xhol, Clal, Sad, EagI, and Smal sites.
  • Preferred cloning sites are selected from the group consisting of NotI, SnaBI, Sall, and Xhol.
  • the multiple cloning site has a length no greater than about 70 base pairs, and preferably no greater than about 60 base pairs.
  • the multiple restriction enzyme site, or multiple cloning site is located between the 5'LTR and 3'LTR of the retroviral vector.
  • the 5' end of the multiple cloning site is no greater than about 895 base pairs from the 3' end of the 5' LTR, and preferably at least about 375 base pairs from the 3' end of the 5' LTR.
  • the 3' end of the multiple cloning site is no greater than about 40 base pairs from the 5' end of the 3' LTR, and preferably at least 11 base pairs from the 5' end of the 3 ' LTR.
  • Such vectors may be engineered from existing retroviral vectors through genetic engineering techniques known in the art such that the resulting retroviral vector includes at least four cloning sites wherein at least two of the cloning sites are selected from the group consisting of the NotI, SnaBI, Sall, and Xhol cloning sites.
  • the retroviral vector includes each of the NotI, SnaBI, Sall, and Xhol cloning sites.
  • Such a retroviral vector may serve as part of a cloning system for the transfer of genes to eukaryotic cells.
  • a cloning system for the manipulation of genes in a retroviral vector which includes a retroviral vector including a multiple cloning site of the type hereinabove described, and a shuttle cloning vector which includes at least two cloning sites which are compatible with at least two cloning sites selected from the group consisting of NotI, SnaBI, Sall, and Xhol located on the retroviral vector.
  • the shuttle cloning vector also includes at least one desired gene which is capable of being transferred from said shuttle cloning vector to said retroviral vector.
  • the shuttle cloning vector may be constructed from a basic "backbone" vector or fragment to which are ligated one or more linkers which include cloning or restriction enzyme recognition sites. Included in the cloning sites are the compatible, or complementary cloning sites hereinabove described. Genes and/or promoters having ends corresponding to the restriction sites of the shuttle vector may be ligated into the shuttle vector through techniques known in the art.
  • the shuttle cloning vector can be employed to amplify DNA sequences in prokaryotic systems.
  • the shuttle cloning vector may be prepared from plasmids generally used in prokaryotic systems and in particular in bacteria. Thus, for example, the shuttle cloning vector may be derived from plasmids such as pBR322; pUC18; etc.
  • the DNA encoding p15E protein which has been mutated to render a vector particle resistant to inactivation by human serum may be contained in an expression vehicle other than a retroviral vector.
  • expression vehicles include, for example, viral vectors other than retroviral vectors, or any expression plasmid which is capable of being transferred into a cell line which is capable of producing vector particles which include the mutated p15E protein.
  • Such vectors or expression vehicles which contain DNA encoding a mutated env protein such as the mutated p15E protein hereinabove described, are transferred into a pre-packaging cell line to generate vector particles.
  • the pre-packaging cell line contains the gag and pol proteins of the virus, plus a retroviral vector lacking the structural gag, pol, and env proteins.
  • An example of such a pre-packaging cell line is the GPL pre-packaging cell line which consists of an NIH 3T3 mouse fibroblast cell line which contains an expression plasmid for MoMuLV gag-pol protein as well as the retroviral vector LNL6 (Miller, et al., Biotechniques, Vol. 7, pgs. 980-990 (1989)). It is to be understood, however, that the scope of the present invention is not to be limited to any particular pre-packaging cell line.
  • the pre-packaging cell line Upon transfection of the pre-packaging cell line with an expression vehicle containing DNA encoding a mutated env protein, the pre-packaging cell line will generate vector particles. The vector particles are then tested for complement resistance. The vector particles which are shown to be complement resistant (i.e., not inactivated by human serum), therefore, contain complement resistant envelope proteins encoded by a specific envelope expression vehicle.
  • Such an expression vehicle can then be used, by techniques known to those skilled in the art, to produce a packaging cell line which contains an expression vehicle encoding the retroviral gag and pol proteins, and an expression vehicle containing a gene encoding the mutated env protein (such as, for example, an expression vehicle or expression plasmid containing a mutated p15E protein such as hereinabove described), whereby such packaging cell line may be employed to generate vector particles which are resistant to inactivation by human serum.
  • a retroviral vector which lacks the structural gag, pol, and env genes, but includes a desired gene of interest, may be transferred into such a packaging cell line.
  • the packaging cell line may generate vector particles which contain a desired gene(s) of interest, and which are resistant to inactivation by human serum.
  • the vector particles generated from the packaging cell line will not be inactivated when contacted with human serum; and in addition, such vector particles, when engineered with protein containing a receptor binding region for a human receptor, are targetable, whereby the receptor binding region for a human receptor enables the vector particles to bind to a target cell.
  • retroviral vector particles may be directly introduced into the body (e.g., by intravenous, intramuscular, or subcutaneous injection, intranasally, orally, rectally or vaginally), and travel to a desired target cell.
  • Such vector particles therefore, are useful for the introduction of desired heterologous genes into target cells in vivo as a gene therapy procedure.
  • the vectors of the present invention further include at least one heterologous gene.
  • Heterologous or foreign genes which may be placed into the vector or vector particles include, but are not limited to, genes which encode cytokines or cellular growth factors, such as lymphokines, which are growth factors for lymphocytes.
  • Other examples of foreign genes include, but are not limited to, genes encoding Factor VIII, Factor IX, tumor necrosis factors (TNF's), ADA, ApoE, ApoC, and Protein C.
  • the vectors of the present invention include one or more promoters.
  • Suitable promoters which may be employed include, but are not limited to, the retroviral LTR; the SV40 promoter; and the human cytomegalovirus (CMV) promoter described in Miller, et al., Biotechniques, Vol. 7, No. 9, pgs. 980-990 (1989), or any other promoter (eg., cellular promoters such as eukaryotic cellular promoters including, but not limited to, the histone, pol III, and ⁇ -actin promoters).
  • Other viral promoters which may be employed include, but are not limited to adenovirus promoters, TK promoters, and B19 parvovirus promoters. The selection of a suitable promoter will be apparent to those skilled in the art from the teachings contained herein.
  • the vectors of the present invention may contain regulatory elements, where necessary, to ensure tissue specific expression of the desired heterologous gene(s), and/or to regulate expression of the heterologous gene(s) in response to cellular or metabolic signals.
  • retroviral vector particles other viral vector particles (such as, for example, adenovirus and adeno-associated virus particles), or synthetic particles may be constructed wherein a region of the envelope protein in the vector particle may be mutated such that the vector particle becomes resistant to inactivation by human serum, thereby making such vector particles suitable for in vivo administration.
  • viral vector particles such as, for example, adenovirus and adeno-associated virus particles
  • synthetic particles may be constructed wherein a region of the envelope protein in the vector particle may be mutated such that the vector particle becomes resistant to inactivation by human serum, thereby making such vector particles suitable for in vivo administration.
  • Plasmid pCE2 was constructed from pBR322 such that the resulting plasmid pCE2 includes genes encoding the envelope proteins gp70 and p15E.
  • pBR322 ( Figure 1) was cut with EcoRI and filled in to destroy the EcoRI site to give pBR322 Rl .
  • pBR322 R1 was then cut with Ndel and filled in to destroy the Ndel site to give pBR322 R N.
  • pBR322 R N was digested with HindIII and EcoRV, and cloned into the Hindlll/EcoRV fragment was a Hindlll/Fspl cassette containing the gp70 and p15E genes under the control of a cytomegalovirus (CMV) intermediate early promoter with a polyA (adenine) tail from SV40 ( Figure 2) from plasmid pCEE. ( Figure 3).
  • CMV cytomegalovirus
  • the Hindlll/Fspl cassette obtained from plasmid pCEE contains a CMV intermediate early promoter in which the Ball/SacII (bp 21 to bp 766) was converted to an Hindlll/Sall fragment by linker addition; the ecotropic envelope Bglll/Nhel fragment (bp 5408 to bp 7847 of MoMuLV, encoding gp70 and p15E) was filled and EcoRI linkers were added; and the SV40 poly A signal from Bel l to BamHI (bp 2770 to bp 2533 ) was cloned into a BamHI site (thereby destroying the Bell site). A Bglll site was added at the 3' end of the gp70 gene. (This addition does not alter any amino acids).
  • the resulting plasmid is pCE2 ( Figure 4. )
  • pUC-E2 plasmid
  • This plasmid is pUC18 ( Figure 5) with the PvuII fragment removed and replaced with EcoRI linkers. Such was accomplished by digesting pUC18 with PvuII to remove a 322 bp PvuII fragment, and EcoRI linkers were then added.
  • the MoMuLV ecotropic envelope gene i.e., the gp70 and p15E genes from pCE2
  • Bglll site gp70 and p15E genes from pCE2
  • Nhel site 7847
  • PCR primers are then synthesized to encode the following mutations in the p15E protein (using pCE2 as a template):
  • Amino acid residue 117 is changed from Arg to Glu, and amino acid residue 122 is changed from Glu to Gln;
  • Amino acid residue 104 is changed from Arg to His
  • amino acid residue 105 is changed from Asp to Asn
  • amino acid residue 109 is changed from Lys to Gln
  • amino acid residue 111 is changed from Arg to Gln
  • Amino acid residue 104 is changed from Arg to His
  • amino acid residue 105 is changed from Asp to Asn
  • amino acid residue 109 is changed from Lys to Gln
  • amino acid residue 111 is changed from Arg to Gln
  • amino acid residue 117 is changed from Arg to Glu
  • amino acid residue 122 is changed from Glu to Gln.
  • Each PCR product is digested with Spel and PvuII, and cloned into pUC-E2 at the unique Spel and PvuII sites.
  • the resulting plasmids are then sequenced to confirm the point mutations. DNA fragments bearing these mutations are then subcloned into the expression plasmid pCE2.
  • pCE2 is digested with EcoRI and the envelope DNA fragment is removed and replaced with the EcoRI envelope fragment from the pUC-E2 plasmids.
  • the resulting pCE2 plasmids are then checked for orientation of the EcoRI fragment and sequenced again (only at the cloning site junctions and at the regions bearing the point mutations) to confirm the presence of the newly created mutated p15E genes.
  • the resulting expression plasmids are identified as follows:
  • pCR68 - includes mutations in which amino acid residue 117 is changed from Arg to Glu, and amino acid residue 122 is changed from Glu to Gln;
  • pCR69 - includes mutations in which amino acid residue 104 is changed from Arg to His, amino acid residue 105 is changed from Asp to Asn, amino acid residue 109 is changed from Lys to Gln, and amino acid residue 111 is changed from Arg to Gln; and
  • pCR70 - includes mutations in which amino acid residue 104 is changed from Arg to His, amino acid residue 105 is changed from Asp to Asn, amino acid residue 109 is changed from Lys to Gln, amino acid residue 111 is changed from Arg to Gln, amino acid residue 117 is changed from Arg to Glu, and amino acid residue 122 is changed from Glu to Gln.
  • Plasmids pCR68, pCR69, and pCR70 are transfected separately into the GPL pre-packaging cell line.
  • the GPL pre-packaging cell line consists of an NIH 3T3 mouse fibroblast cell line which contains an expression plasmid for MoMuLV gag-pol protein as well as the retroviral vector LNL6 (Miller, et al., 1989).
  • the GPL packaging cell line produces vector particles. Transiently expressed vector particles are collected with cell supernatant at 48-72 hrs. post-transfection.
  • the vector particles generated as hereinabove described may then be assayed for vector titer by techniques known to those skilled in the art.
  • the vector particles may also be collected in viral supernatant and concentrated, if necessary, according to procedures known to those skilled in the art in order to employ such vector particles in assays or in therapeutic procedures.
  • Advantages of the present invention include the ability to introduce vector particles directly into a human patient whereby the vector particle is not lysed or inactivated by human serum upon such introduction.
  • the vector particles of the present invention enable one to deliver desired genes to a patient in vivo.
  • Such vector particles may also be engineered such that they are "targetable”, as well as injectable, thereby enabling the vector particles to travel directly to a target cell or tissue without being lysed or inactivated by human serum.
  • ADDRESSEE Carella, Byrne, Bain,

Abstract

Particule vecteur rétrovirale résistante à l'inactivation par le sérum humain. Les particules vecteurs comprennent de préférence la protéine p15E, au moins une partie de l'ADN codant la protéine p15E étant mutée de sorte que la particule vecteur devienne résistante à l'inactivation par le sérum humain. Les particules vecteurs peuvent comprendre en outre une protéine contenant une région de liaison de récepteur qui se lie au récepteur d'une cellule cible humaine, ce qui permet l'introduction directe in vivo de gènes hétérologues requis, de sorte que la particule vecteur comprenant le gène hétérologue se dirige directement vers une cellule ou des tissus cibles.
PCT/US1993/004706 1992-06-10 1993-05-14 Particules vecteurs resistantes a l'inactivation par le serum humain Ceased WO1993025698A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP6501479A JPH09507741A (ja) 1992-06-10 1993-05-14 ヒト血清による不活性化に耐性のあるベクター粒子
EP93913964A EP0644946A4 (fr) 1992-06-10 1993-05-14 Particules vecteurs resistantes a l'inactivation par le serum humain.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US896,603 1978-04-14
US89660392A 1992-06-10 1992-06-10

Publications (2)

Publication Number Publication Date
WO1993025698A1 WO1993025698A1 (fr) 1993-12-23
WO1993025698A9 true WO1993025698A9 (fr) 1994-06-09

Family

ID=25406489

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/004706 Ceased WO1993025698A1 (fr) 1992-06-10 1993-05-14 Particules vecteurs resistantes a l'inactivation par le serum humain

Country Status (4)

Country Link
EP (1) EP0644946A4 (fr)
JP (1) JPH09507741A (fr)
CA (1) CA2137361A1 (fr)
WO (1) WO1993025698A1 (fr)

Families Citing this family (247)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003834A1 (fr) * 1993-07-28 1995-02-09 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services PRE-LIAISON DE PARTICULES DE VECTEURS RETROVIRAUX DE COMPOSANTS DE COMPLEMENT DESTINEE A PERMETTRE UNE THERAPIE GENIQUE HUMAINE $i(IN VIVO)
CA2196208A1 (fr) * 1994-08-17 1996-02-22 Michael Pensiero Vecteurs retroviraux produits par des lignees de cellules productrices resistantes a la lyse par le serum humain
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
GB9517263D0 (en) * 1995-08-23 1995-10-25 Cancer Res Campaign Tech Expression systems
GB9525639D0 (en) * 1995-12-15 1996-02-14 Isis Innovation Improved retroviral vectors
WO1998000542A2 (fr) * 1996-07-03 1998-01-08 Chiron Corporation Procedes d'administration d'excipients d'apport de genes recombines dans le traitement de l'hemophilie
JP2001500738A (ja) 1996-09-17 2001-01-23 カイロン コーポレイション 細胞内疾患を処置するための組成物および方法
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
WO1999006576A1 (fr) 1997-08-04 1999-02-11 Calydon, Inc. Sequence stimulatrice de la kallicreine glandulaire chez l'homme, vecteurs comprenant cette sequence et procedes d'utilisation de ces derniers
CA2306443A1 (fr) 1997-10-14 1999-04-22 Darwin Molecular Corporation Mutants et proteines de fusion de thymidine kinase presentant des activites de thymidine kinase et de guanylate kinase
DE69841807D1 (de) 1997-11-06 2010-09-16 Novartis Vaccines & Diagnostic Neisseriale antigene
ES2333071T5 (es) 1998-01-14 2015-08-17 Novartis Vaccines And Diagnostics S.R.L. Antígenos de Neisseria meningitidis
MX343744B (es) 1998-05-01 2016-11-22 J Craig Venter Inst Inc Antigenos de neisseria meningitidis y composiciones que los contienen.
ATE386804T1 (de) 1998-10-15 2008-03-15 Novartis Vaccines & Diagnostic Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
EP1133558B2 (fr) 1998-11-27 2016-04-13 UCB Pharma S.A. Compositions et methodes d'augmentation de la mineralisation de la substance osseuse
ATE408695T1 (de) 1998-12-16 2008-10-15 Novartis Vaccines & Diagnostic Menschliche cyclin-abhängige kinase (hpnqalre)
US7063850B1 (en) 1998-12-22 2006-06-20 University Of Tennessee Research Foundation Protective antigen of group A Streptococci
EP2206785A1 (fr) 1998-12-31 2010-07-14 Novartis Vaccines and Diagnostics, Inc. Expression améliorée de polypeptides HIV et production de particules de type virus
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US6911429B2 (en) 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
PT1228217E (pt) 1999-04-30 2013-01-28 Novartis Vaccines & Diagnostic Antígenos de neisseria conservados
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
AU784203B2 (en) 1999-10-29 2006-02-23 Glaxosmithkline Biologicals S.A. Neisserial antigenic peptides
WO2001036640A2 (fr) 1999-11-18 2001-05-25 Chiron Corporation Gene humain fgf-21 et produits d'expression genique
MXPA02006962A (es) 2000-01-17 2002-12-13 Chiron Spa Vacuna de vesicula de membrana exterior que comprende proteinas de membrana exterior de neisseria meningitidis serogrupo b.
EP1854476A3 (fr) 2000-02-09 2008-05-07 Bas Medical, Inc. Utilisation de la relaxine pour traiter des maladies associées à la vasoconstriction
AU2001249125A1 (en) 2000-03-08 2001-09-17 Chiron Corporation Human fgf-23 gene and gene expression products
EP1950297A2 (fr) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions et procédés de traitement de maladie néoplastique utilisant la chimiothérapie et des sensibilisateurs à rayonnement
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
ES2305087T3 (es) 2000-06-15 2008-11-01 Novartis Vaccines And Diagnostics, Inc. Polinucleotidos relacionados con el cancer de colon.
EP2277896A1 (fr) 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines dérivés des groupes de streptocoques A et B
CA2430379A1 (fr) 2000-12-07 2002-06-13 Chiron Corporation Retrovirus endogenes regules positivement dans le cancer de la prostate
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2002241922B2 (en) 2001-01-17 2007-10-25 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
CA2446112C (fr) 2001-05-08 2011-04-26 Darwin Molecular Corporation Methode de regulation de la fonction immune chez les primates a l'aide de la proteine foxp3
WO2003004620A2 (fr) 2001-07-05 2003-01-16 Chiron, Corporation Polynucleotides codant des polypeptides de type c du vih antigeniques, polypeptides et leurs utilisations
EP1409694A4 (fr) 2001-07-05 2006-02-08 Chiron Corp Polynucleotides codant pour des polypeptides antigeniques du vih de sous-type b et/ou de sous-type c, polypeptides et leurs utilisations
WO2003065973A2 (fr) 2001-10-26 2003-08-14 Id Biomedical Corporation Of Washington Compositions de vaccins multivalents a base de streptocoques et procedes d'utilisation
AU2002359446B2 (en) 2001-11-09 2008-12-04 Georgetown University Novel isoforms of vascular endothelial cell growth inhibitor
US20050106162A1 (en) 2001-12-12 2005-05-19 Guido Grandi Immunisation against chlamydia trachomatis
EP1472375B1 (fr) 2002-01-08 2009-04-01 Novartis Vaccines and Diagnostics, Inc. Produits geniques a expression differenciee dans des cellules cancereuses du sein et methodes d'utilisation associees
IL163988A0 (en) 2002-03-15 2005-12-18 Wyeth Corp Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
JP2005520543A (ja) 2002-03-21 2005-07-14 サイグレス ディスカバリー， インコーポレイテッド 癌における新規組成物および方法
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US8518694B2 (en) 2002-06-13 2013-08-27 Novartis Vaccines And Diagnostics, Inc. Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
SI1556083T1 (sl) 2002-10-08 2011-05-31 Rinat Neuroscience Corp Postopki za zdravljenje postoperativne bolečine z dajanjem protitelesa proti živčnemu rastnemu faktorju in sestavki, ki ga vsebujejo
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
ATE553128T1 (de) 2002-12-24 2012-04-15 Rinat Neuroscience Corp Anti-ngf-antikörper und verfahren zu ihrer verwendung
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US20070149449A1 (en) 2003-02-14 2007-06-28 Morris David W Therapeutic targets in cancer
MXPA05008815A (es) 2003-02-19 2006-05-25 Rinat Neuroscience Corp Metodos para tratar el dolor al administrar un antagonista del factor de crecimiento de nervios y un farmaco antiinflamatorio no esteroidal y composiciones que contienen los mismos.
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
EP1619951B1 (fr) 2003-04-21 2011-06-22 Epeius Biotechnologies Corporation Methodes et compositions destinees a traiter des troubles
US9532994B2 (en) 2003-08-29 2017-01-03 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
BRPI0417270A (pt) 2003-12-23 2007-03-27 Rinat Neuroscience Corp anticorpos agonistas antitrkc e métodos para utilização dos mesmos
WO2005093064A1 (fr) 2004-03-29 2005-10-06 Galpharma Co., Ltd. Protéine de modification de galectine-9 novatrice et utilisation de celle-ci
SG152226A1 (en) 2004-04-07 2009-05-29 Rinat Neuroscience Corp Methods for treating bone cancer pain by administering a nerve growth factor antagonist
EP1789593B1 (fr) 2004-07-09 2017-03-15 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Formes solubles de glycoproteine g des virus hendra
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
EP2298807A3 (fr) 2004-07-30 2011-05-18 Rinat Neuroscience Corp. Anticorps anti peptide amyloide beta, et leurs procedes d' utilisation
ATE552267T1 (de) 2005-02-18 2012-04-15 Novartis Vaccines & Diagnostic Immungene von uropathogenen escherichia coli
EP1865981A2 (fr) 2005-04-07 2007-12-19 Chiron Corporation Cacna1e dans le diagnostic, la detection et le traitement du cancer
US20090220495A1 (en) 2005-04-07 2009-09-03 Abdallah Fanidi Cancer Related Genes (PRLR)
AU2006272713A1 (en) 2005-07-22 2007-02-01 Y's Therapeutics Co, Ltd. Anti-CD26 antibodies and methods of use thereof
PT1912675E (pt) 2005-07-25 2014-05-09 Emergent Product Dev Seattle Moléculas de ligaçao especificas para cd37 e especificas para cd20
EP1957106B2 (fr) 2005-11-14 2019-07-24 Teva Pharmaceuticals International GmbH Anticorps antagonistes orientes contre un peptide lie au gene de la calcitonine, et procedes d'utilisation correspondants
WO2007088479A1 (fr) 2006-02-02 2007-08-09 Rinat Neuroscience Corp. Procédés de traitement de l'obésité par administration d'un antagoniste trkb
AU2007217366A1 (en) 2006-02-27 2007-08-30 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
BRPI0712850A8 (pt) 2006-06-07 2018-05-02 Bioalliance Cv anticorpos que reconhecem um epitopo contendo carboidrato em cd-43 e cea expressados em células cancerígenas e métodos de uso dos mesmos
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
WO2007146968A2 (fr) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Protéines de liaison monocaténaires polyvalentes dotées d'une fonction d'effecteur
JP2010500399A (ja) 2006-08-16 2010-01-07 ノバルティス アーゲー 尿路病原性大腸菌由来の免疫原
CA2662921C (fr) 2006-09-26 2018-11-20 Infectious Disease Research Institute Vaccin, compositions pharmaceutiques, necessaires et utilisations de ceux-ci pour stimuler une reponse immunitaire avec un adjuvant glucopyranosyl lipide synthetique
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8673859B2 (en) 2007-03-20 2014-03-18 New York University GM-CSF cosmeceutical compositions and methods of use thereof
US20100261640A1 (en) 2007-04-10 2010-10-14 Branco Luis M Soluble and membrane anchored forms of lassa virus subunit proteins
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
CN101951915A (zh) 2007-12-03 2011-01-19 加利福尼亚大学董事会 用于刺猬蛋白信号、骨诱导、抗脂肪形成和wnt信号的激活的氧固醇
CA2709135C (fr) 2007-12-17 2018-06-05 Pfizer Limited Traitement de la cystite interstitielle
US7982017B2 (en) 2007-12-18 2011-07-19 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
US10000568B2 (en) 2008-04-10 2018-06-19 Cell Signaling Technology, Inc. Compositions and methods for detecting EGFR in cancer
CN102099377A (zh) 2008-04-11 2011-06-15 新兴产品开发西雅图有限公司 Cd37免疫治疗剂及其与双功能化学治疗剂的联合
WO2009150623A1 (fr) 2008-06-13 2009-12-17 Pfizer Inc Traitement de la prostatite chronique
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
US20110287026A1 (en) 2008-09-23 2011-11-24 President And Fellows Of Harvard College Sirt4 and uses thereof
WO2010080985A1 (fr) 2009-01-08 2010-07-15 Dana-Farber Cancer Institute, Inc. Compositions et procédés pour induire la différenciation du tissu adipeux brun
WO2010086828A2 (fr) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Anticorps monoclonaux agonistes anti-trkb
RU2011140508A (ru) 2009-03-06 2013-04-20 Новартис Аг Антигены хламидии
US20100297127A1 (en) 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
EP2419129A2 (fr) 2009-04-14 2012-02-22 Novartis AG Compositions pour l'immunisation contre staphylococcus aureus
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
WO2010146511A1 (fr) 2009-06-17 2010-12-23 Pfizer Limited Traitement d'une vessie hyperactive
EP2449381A1 (fr) * 2009-06-30 2012-05-09 Abbott Laboratories Marqueurs d'infection par le virus xmrv et utilisations afférentes
CN102770443A (zh) 2009-07-16 2012-11-07 诺华有限公司 脱毒大肠杆菌免疫原
WO2011038063A1 (fr) 2009-09-28 2011-03-31 The Trustees Of The University Of Pennsylvania Procédé pour diagnostiquer et traiter la cystite interstitielle
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
CA2787628A1 (fr) 2010-01-21 2011-07-28 Dana-Farber Cancer Institute, Inc. Plate-forme de criblage genetique specifique du contexte pour assister la decouverte de genes et la validation de cibles
TWI596114B (zh) 2010-02-24 2017-08-21 雷那特神經科學股份有限公司 拮抗劑抗-ｉｌ-７受體抗體及方法
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
KR20150002894A (ko) 2010-03-11 2015-01-07 리나트 뉴로사이언스 코프. ｐＨ 의존성 항원 결합을 갖는 항체
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011133931A1 (fr) 2010-04-22 2011-10-27 Genentech, Inc. Utilisation d'antagonistes d'il-27 pour traiter une maladie intestinale inflammatoire
JP2013533286A (ja) 2010-07-30 2013-08-22 セントルイス ユニバーシティ 疼痛を治療する方法
WO2012064743A2 (fr) 2010-11-08 2012-05-18 The Johns Hopkins University Procédés d'amélioration de la fonction cardiaque
EP2663868A2 (fr) 2010-12-01 2013-11-20 The University of North Carolina at Chapel Hill Procédés et compositions destinés à cibler des sites de croissance néovasculaire
WO2012072769A1 (fr) 2010-12-01 2012-06-07 Novartis Ag Epitopes rrgb de pneumocoque et combinaisons de variantes
CA2832307A1 (fr) 2011-04-08 2012-10-18 Immune Design Corp. Compositions immunogenes et leurs procedes d'utilisation pour induire des reponses immunitaires humorales et cellulaires
US20130071375A1 (en) 2011-08-22 2013-03-21 Saint Louis University Compositions and methods for treating inflammation
WO2013028527A1 (fr) 2011-08-23 2013-02-28 Indiana University Research And Technology Corporation Compositions et procédés pour traiter le cancer
US8969519B2 (en) 2011-09-13 2015-03-03 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using FNDC5
WO2013055911A1 (fr) 2011-10-14 2013-04-18 Dana-Farber Cancer Institute, Inc. Biomarqueur znf365/zfp365 pouvant prévoir une réponse anticancéreuse
TWI495644B (zh) 2011-11-11 2015-08-11 Rinat Neuroscience Corp 營養層細胞表面抗原（Ｔｒｏｐ－２）之專一性抗體類及彼等之用途
WO2013093693A1 (fr) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Anticorps spécifiques de staphylococcus aureus et leurs utilisations
AU2012356206A1 (en) 2011-12-22 2014-06-26 Rinat Neuroscience Corp. Human growth hormone receptor antagonist antibodies and methods of use thereof
SI2811981T1 (sl) 2012-02-07 2019-08-30 Infectious Disease Research Institute Izboljšanje adjuvantne formulacije, ki obsegajo TLR4 agoniste in postopki za uporabo le-teh
PL2844282T3 (pl) 2012-05-04 2019-11-29 Pfizer Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
EP2847206A4 (fr) 2012-05-07 2016-01-20 Univ California Oxy133, un analogue de l'oxystérol, induisant l'ostéo-genèse et la signalisation hedgehog et inhibant l'adipogenèse
AU2013262691B2 (en) 2012-05-16 2018-12-20 Immune Design Corp. Vaccines for HSV-2
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
MX2015005874A (es) 2012-11-09 2015-09-10 Pfizer Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos.
WO2014153258A2 (fr) 2013-03-14 2014-09-25 Epeius Biotechnologies Corporation Gène codant pour des thymidine kinases améliorées
CA3208188A1 (fr) 2013-03-15 2014-09-25 Takeda Pharmaceutical Company Limited Anticorps anti-kallicreine plasmatique
EP3711768A1 (fr) 2013-04-18 2020-09-23 Immune Design Corp. Monothérapie de gla destinée à être utilisée dans le traitement du cancer
AU2014259672A1 (en) 2013-05-02 2015-12-03 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
CN105189560A (zh) 2013-05-07 2015-12-23 瑞纳神经科学公司 抗胰高血糖素受体抗体和其使用方法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CN106103716A (zh) 2013-07-12 2016-11-09 乔治亚洲立大学研究基金会 Rna干扰dna聚合酶并抑制dna合成的方法及其复合物组分
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
AU2014298040B2 (en) 2013-08-02 2018-04-26 Pfizer Inc. Anti-CXCR4 antibodies and antibody-drug conjugates
BR112016009797A2 (pt) 2013-11-13 2017-12-05 Bristol Myers Squibb Co anticorpos específicos de ligante 1a do tipo fator de necrose tumoral e composições e usos dos mesmos
WO2015087187A1 (fr) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anticorps anti-sclérostine
WO2015109212A1 (fr) 2014-01-17 2015-07-23 Pfizer Inc. Anticorps anti-il-2 et compositions et utilisations de ceux-ci
KR102274964B1 (ko) 2014-03-21 2021-07-09 테바 파마슈티컬스 인터내셔널 게엠베하 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
EP3134546A4 (fr) 2014-04-24 2017-12-06 Dana-Farber Cancer Institute, Inc. Suppresseur de tumeur et biomarqueurs oncogènes prédictifs de réponse à un inhibiteur de point de contrôle anti-immunitaire
US10308697B2 (en) 2014-04-30 2019-06-04 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
US10329556B2 (en) 2014-05-13 2019-06-25 Bioatla, Llc Conditionally active biological proteins
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
AU2015308818B2 (en) 2014-08-28 2021-02-25 Bioatla Llc Conditionally active chimeric antigen receptors for modified T-cells
US11111288B2 (en) 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
KR20170044115A (ko) 2014-09-03 2017-04-24 바이오아트라, 엘엘씨 동일한 진핵생물 세포 생산 숙주 내 조건부 활성 생체 단백질의 발견 및 제조
EP3191507A1 (fr) 2014-09-09 2017-07-19 Unum Therapeutics Récepteurs chimériques et utilisations de ceux-ci en thérapie immunitaire
WO2016057367A1 (fr) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Biomarqueurs à base d'angiopoïétine -2 utilisés pour la prédiction de la réponse de point de contrôle anti-immunitaire
EP3204119B1 (fr) 2014-10-09 2021-06-09 Dana-Farber Cancer Institute, Inc. Schéma posologique d'il-2 variables multiples pour le traitement de troubles immunitaires
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
KR20240091031A (ko) 2015-01-02 2024-06-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 및 인자 xii에 대한 이중특이성 항체
EP3265825A4 (fr) 2015-03-06 2018-08-08 Dana-Farber Cancer Institute, Inc. Biomarqueurs pd-l2 prédictifs de réponses d'inhibiteurs de la voie pd-1 dans les cancers oesophagogastriques
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
PL3283106T3 (pl) 2015-04-13 2022-05-02 Pfizer Inc. Przeciwciała terapeutyczne i ich zastosowania
US10877045B2 (en) 2015-07-21 2020-12-29 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
WO2017015431A1 (fr) 2015-07-21 2017-01-26 Dyax Corp. Inhibiteur d'anticorps monoclonal du facteur xiia
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
KR102536303B1 (ko) 2015-08-19 2023-05-26 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
DK3922645T3 (da) 2015-09-15 2025-06-16 Scholar Rock Inc Anti-pro/latent-myostatin-antistoffer og anvendelse heraf
WO2017053469A2 (fr) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Polypeptides de liaison à cd3
WO2017066760A1 (fr) 2015-10-16 2017-04-20 The Trustees Of Columbia University In The City Of New York Compositions et méthodes d'inhibition d'antigènes spécifiques à une lignée
EP3362074B1 (fr) 2015-10-16 2023-08-09 President and Fellows of Harvard College Modulation de pd-1 des lymphocytes t régulateurs pour réguler les réponses immunitaires effectrices des lymphocytes t
CN109071648B (zh) 2015-10-23 2022-07-19 辉瑞有限公司 抗il-2抗体及其组合物和用途
WO2017075037A1 (fr) 2015-10-27 2017-05-04 Scholar Rock, Inc. Facteurs de croissance amorcés et leurs utilisations
CA3002676A1 (fr) 2015-10-29 2017-05-04 Dana-Farber Cancer Institute, Inc. Procedes pour identifier, evaluer, prevenir et traiter des troubles metaboliques au moyen de pm20d1 et d'acides amines n-lipides
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
US11066465B2 (en) 2015-12-30 2021-07-20 Kodiak Sciences Inc. Antibodies and conjugates thereof
TW201936640A (zh) 2016-01-21 2019-09-16 美商輝瑞股份有限公司 對表皮生長因子受體變異體ｉｉｉ具特異性之抗體類及彼等之用途
CN110753755B (zh) 2016-03-21 2023-12-29 丹娜法伯癌症研究院 T细胞耗竭状态特异性基因表达调节子及其用途
KR20240148936A (ko) 2016-05-13 2024-10-11 바이오아트라, 인코퍼레이티드 항 ror2 항체, 항체 단편 및 이의 면역접합체와 이것들의 용도
IL314130A (en) 2016-05-16 2024-09-01 Access To Advanced Health Inst Formulation containing tlr agonist and methods of use
IL315825A (en) 2016-06-01 2024-11-01 Access To Advanced Health Inst Nanoalum particles containing a fixing factor
EP3478325B1 (fr) 2016-07-01 2024-07-17 Research Development Foundation Élimination de cellules proliférantes de greffons dérivés de cellules souches
EP3515559B1 (fr) 2016-09-20 2025-05-21 Dana-Farber Cancer Institute, Inc. Compositions et méthodes pour l'identification, l'évaluation, la prévention et le traitement de la lma au moyen de biomarqueurs usp10 et de modulateurs
US20180119141A1 (en) 2016-10-28 2018-05-03 Massachusetts Institute Of Technology Crispr/cas global regulator screening platform
WO2018148246A1 (fr) 2017-02-07 2018-08-16 Massachusetts Institute Of Technology Procédés et compositions pour circuits génétiques à guidage par arn
AU2018226646A1 (en) 2017-03-03 2019-09-19 Rinat Neuroscience Corp. Anti-GITR antibodies and methods of use thereof
JP7177076B2 (ja) 2017-03-16 2022-11-22 ファイザー・インク チロシン原栄養性
WO2018191548A2 (fr) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Anticorps antagonistes du facteur d du complément et leurs conjugués
CA3006798A1 (fr) 2017-06-02 2018-12-02 Pfizer Inc. Anticorps specifiques a la flt3 et leurs utilisations
US11820822B2 (en) 2017-06-06 2023-11-21 Dana-Farber Cancer Institute, Inc. Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways
AU2018102201A4 (en) 2017-06-13 2021-01-21 Bostongene Corporation Systems and methods for identifying cancer treatments from normalized biomarker scores
CN110997002A (zh) 2017-07-13 2020-04-10 麻省理工学院 靶向hdac2-sp3复合体以增强突触功能
WO2019016784A1 (fr) 2017-07-21 2019-01-24 Universidade De Coimbra Anticorps anti-nucléoline
CN111093715A (zh) 2017-09-18 2020-05-01 儿童医院医疗中心 强绝缘子和其在基因递送中的用途
KR20210027230A (ko) 2017-10-04 2021-03-10 옵코 파마슈티칼스, 엘엘씨 암의 개인 맞춤형 치료에 관한 물품 및 방법
US11266743B2 (en) 2017-10-25 2022-03-08 The Administrators Of The Tulane Educational Fund Peptide compositions and methods of use thereof
DK3625263T3 (da) 2017-10-27 2025-06-30 Univ New York Anti-galectin- 9-antistoffer og anvendelser deraf
BR112020015662A2 (pt) 2018-02-01 2020-12-08 Pfizer Inc. Receptores de antígeno quimérico direcionados a cd70
EP3746482A1 (fr) 2018-02-01 2020-12-09 Pfizer Inc. Anticorps spécifiques à cd70 et leurs utilisations
MX387358B (es) 2018-02-28 2025-03-18 Pfizer Variantes de il-15 y usos de las mismas
EP3759125A4 (fr) 2018-02-28 2021-12-08 Dana-Farber Cancer Institute, Inc. Méthodes de traitement du cancer à l'aide de combinaisons d'agents de blocage anti-btnl2 et points de contrôle immunitaires
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CN112153977B (zh) 2018-04-06 2025-01-10 丹娜法伯癌症研究院 作为hhla2受体的kir3dl3、抗hhla2抗体及其用途
MX2020012539A (es) 2018-05-23 2021-02-16 Pfizer Anticuerpos especificos para cd3 y sus usos.
JP7057843B2 (ja) 2018-05-23 2022-04-20 ファイザー・インク ＧＵＣＹ２ｃに特異的な抗体及びその使用
EP3817763B1 (fr) 2018-07-03 2025-09-03 SOTIO Biotech Inc. Récepteurs chimériques en association avec des molécules de métabolisme trans améliorant l'importation de glucose et leurs utilisations thérapeutiques
CA3108126A1 (fr) 2018-08-14 2020-02-20 Sotio, LLC Recepteurs d'antigene chimeriques en association avec des molecules de trans-metabolisme modulant le cycle de krebs et leurs utilisations therapeutiques
MX2021002415A (es) 2018-08-28 2021-09-21 Vor Biopharma Inc Celulas madre hematopoyeticas modificadas geneticamente y usos de las mismas.
CN112805301B (zh) 2018-10-15 2023-07-21 安立玺荣生医(香港)有限公司 粒细胞-巨噬细胞集落刺激因子的抗体及其用途
AU2019401647A1 (en) 2018-12-21 2021-07-08 Multitude Inc. Antibodies specific to MUC18
EP3914269B1 (fr) 2019-01-23 2024-07-17 New York University Anticorps spécifiques de la chaîne delta 1 du récepteur des lymphocytes t
WO2020223121A1 (fr) 2019-04-30 2020-11-05 Dana-Farber Cancer Institute, Inc. Méthodes de traitement du cancer à l'aide de combinaisons d'agents anti-cx3cr1 et d'agents de blocage de points de contrôle immunitaires
EP3994696B1 (fr) 2019-07-03 2025-05-14 BostonGene Corporation Systèmes et procédés pour la préparation d'échantillons, le séquençage d'échantillons, la correction de biais de données de séquençage et le contrôle de qualité
WO2021071830A1 (fr) 2019-10-07 2021-04-15 University Of Virginia Patent Foundation Modulation de vaisseaux lymphatiques dans une maladie neurologique
EP4041312A4 (fr) 2019-10-10 2023-12-20 Kodiak Sciences Inc. Procédés de traitement d'un trouble oculaire
EP4041773A1 (fr) 2019-10-11 2022-08-17 Beth Israel Deaconess Medical Center, Inc. Anticorps anti-tn et leurs utilisations
WO2021151079A1 (fr) 2020-01-24 2021-07-29 University Of Virginia Patent Foundation Modulation de vaisseaux lymphatiques dans une maladie neurologique
EP4093513A4 (fr) 2020-01-24 2024-05-08 Dana-Farber Cancer Institute, Inc. Utilisations de biomarqueurs pour améliorer une immunothérapie
WO2021205325A1 (fr) 2020-04-08 2021-10-14 Pfizer Inc. Anticorps anti-gucy2c et leurs utilisations
US20230181750A1 (en) 2020-05-06 2023-06-15 Crispr Therapeutics Ag Mask peptides and masked anti-ptk7 antibodies comprising such
EP4165071A4 (fr) 2020-06-15 2024-07-17 Academia Sinica Protéine de fusion ac2-fc humanisée pour le traitement et la prévention d'une infection par sars-cov-2
TW202216779A (zh) 2020-07-17 2022-05-01 美商輝瑞股份有限公司 治療性抗體類和彼等之用途
WO2022023972A1 (fr) 2020-07-30 2022-02-03 Pfizer Inc. Cellules ayant des duplications de gènes et leurs utilisations
WO2022086852A2 (fr) 2020-10-19 2022-04-28 Dana-Farber Cancer Institute, Inc. Biomarqueurs germinaux de la réponse clinique et du bénéfice d'un traitement par inhibiteur de points de contrôle immunitaire
US20240024474A1 (en) 2020-11-13 2024-01-25 David Avigan Personalized fusion cell vaccines
WO2022120256A2 (fr) 2020-12-04 2022-06-09 Bostongene Corporation Techniques d'apprentissage machine hiérarchique permettant d'identifier des catégories moléculaires à partir de données d'expression
US20240158864A1 (en) 2021-01-25 2024-05-16 Dana-Farber Cancer Institute, Inc. Methods and compositions for identifying neuroendocrine prostate cancer
US20220372580A1 (en) 2021-04-29 2022-11-24 Bostongene Corporation Machine learning techniques for estimating tumor cell expression in complex tumor tissue
WO2022261183A2 (fr) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions et procédés de traitement et/ou d'identification d'un agent pour le traitement de cancers intestinaux
CA3227875A1 (fr) 2021-08-02 2023-02-09 Pfizer Inc. Vecteurs d'expression ameliores et leurs utilisations
WO2023049933A1 (fr) 2021-09-27 2023-03-30 Sotio Biotech Inc. Polypeptides récepteurs chimériques en combinaison avec des molécules de métabolisme trans qui réorientent des métabolites de glucose hors de la voie de glycolyse et leurs utilisations thérapeutiques
MX2024005926A (es) 2021-11-16 2024-06-04 Sotio Biotech Inc Tratamiento de pacientes con liposarcoma mixoide/de celulas redondas.
WO2023097119A2 (fr) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Méthodes et compositions pour moduler riok2
EP4473288B1 (fr) 2022-01-31 2025-10-29 BostonGene Corporation Techniques d'apprentissage automatique pour cytométrie
EP4473096A1 (fr) 2022-02-02 2024-12-11 Pfizer Inc. Prototrophie cystéinique
JP2025506679A (ja) 2022-02-16 2025-03-13 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｆｎｄｃ５又はその生物学的に活性な断片を調節する薬剤を使用する、病理学的アルファ－シヌクレインを低下させるための方法
WO2024015561A1 (fr) 2022-07-15 2024-01-18 Bostongene Corporation Techniques de détection d'une déficience de recombinaison homologue (hrd)
WO2024040207A1 (fr) 2022-08-19 2024-02-22 Sotio Biotech Inc. Cellules tueuses naturelles (nk) génétiquement modifiées avec des polypeptides récepteurs chimériques en combinaison avec des molécules de trans-métabolisme et leurs utilisations thérapeutiques
EP4572787A1 (fr) 2022-08-19 2025-06-25 SOTIO Biotech Inc. Cellules immunitaires génétiquement modifiées avec des polypeptides récepteurs chimériques en combinaison avec de multiples molécules du métabolisme trans et leurs utilisations thérapeutiques
WO2024215987A1 (fr) 2023-04-14 2024-10-17 Sotio Biotech Inc. CELLULES IMMUNITAIRES POUR LE TRAITEMENT DU CANCER EN COMBINAISON AVEC DES CONJUGUÉS IL-15/IL-15Rα
WO2024215989A1 (fr) 2023-04-14 2024-10-17 Sotio Biotech Inc. CELLULES IMMUNITAIRES MODIFIÉES POUR LE TRAITEMENT D'UN CANCER EN COMBINAISON AVEC DES AGONISTES βγ DU RÉCEPTEUR IL-2/IL-15
WO2025030010A1 (fr) 2023-08-01 2025-02-06 Vor Biopharma Inc. Compositions comprenant des cellules souches hématopoïétiques génétiquement modifiées et leurs méthodes d'utilisation
WO2025034542A1 (fr) 2023-08-04 2025-02-13 Cornell University Panel de signature génique prédisant une réponse cancéreuse à un blocage de point de contrôle immunitaire et radiothérapie
WO2025096811A1 (fr) 2023-10-31 2025-05-08 Bostongene Corporation Technique d'apprentissage automatique pour identifier des sujets répondant à un inhibiteur de point de contrôle immunitaire (ici) et des sujets n'y répondant pas
US20250253011A1 (en) 2024-02-02 2025-08-07 Seven Bridges Genomics Inc. Techniques for improved tumor mutational burden (tmb) determination using a population-specific genomic reference

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3264281B2 (ja) * 1990-06-20 2002-03-11 デイナ・フアーバー・キヤンサー・インステイテユート Ｈｉｖパッケージング配列を含むベクター、パッケージング不全ｈｉｖベクター及びその使用

Similar Documents

Publication Publication Date Title
WO1993025698A9 (fr) Particules vecteurs resistantes a l'inactivation par le serum humain
EP0644946A1 (fr) Particules vecteurs resistantes a l'inactivation par le serum humain
CA2148934C (fr) Particules vectorielles ciblables
US5925345A (en) Vectors including foreign genes and negative selective markers
US5449614A (en) Recombinant retroviruses with amphotropic and ecotropic host ranges
US5672510A (en) Retroviral vectors
AU733016B2 (en) Methods and compositions for transforming cells
Buchholz et al. In vivo selection of protease cleavage sites from retrovirus display libraries
US5886166A (en) Retroviral vector, a replication system for said vector and avian or mammalian cells transfected with said vector
Kim et al. Construction of retroviral vectors with improved safety, gene expression, and versatility
AU737727B2 (en) Modified viral surface proteins for binding to extracellular matrix components
US20030087437A1 (en) Method for gene transfer into target cells with retrovirus
US5747323A (en) Retroviral vectors comprising a VL30-derived psi region
JP2003530064A (ja) 遺伝子治療用のコートタンパク質改変バキュロウイルス−ベクター
US5554524A (en) More complex type retroviruses having mixed type LTR, and uses thereof
US5576201A (en) Retroviral vector particles for transducing non-proliferating cells
WO1998051700A1 (fr) Enveloppes retrovirales a regions polyproline hypervariables modifiees
US5580766A (en) Retroviral vector particles for transducing non-proliferating cells
US6111087A (en) Expression of a foamy virus envelope protein
US5736360A (en) Endothelial cell tropic compositions and methods of making and using the same
US20030129163A1 (en) Retroviral vectors including modified envelope escort proteins
EP0511311A1 (fr) Nouveaux vecteurs retroviraux
US6762031B2 (en) Targeting viral vectors to specific cells
CA2326407C (fr) Vecteurs retroviraux incluant des proteines d'escorte a enveloppe modifiee
AU733948B2 (en) Expression of a modified foamy virus envelope protein